Louis P Garrison
University of Washington
H-index: 40
North America-United States
Top articles of Louis P Garrison
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Using Patient Preferences in Health Technology Assessment: Evaluating Quality-Adjusted Survival Equivalents (QASE) for the Quantification of Non-health Benefits | The Patient-Patient-Centered Outcomes Research | Kevin Marsh Hannah Collacott Jim Thomson Jonathan Mauer Stephen Watt | 2024/2/29 |
Evidence Synthesis and Linkage for Modelling the Cost-Effectiveness of Diagnostic Tests: Preliminary Good Practice Recommendations | Applied Health Economics and Health Policy | Bethany Shinkins A Joy Allen James Karichu Louis P Garrison Brigitta U Monz | 2024/2/5 |
Incorporating Real Option Value in Valuing Innovation: A Way Forward | PharmacoEconomics | Meng Li Louis P Garrison | 2024/2/4 |
Evolving Evidence-Based Value Assessment of One-Time Therapies: Tisagenlecleucel as a Case Study | Applied Health Economics and Health Policy | Theodore Laetsch Jie Zhang Hongbo Yang Yanwen Xie Dudan Zhang | 2024/4/29 |
Multicriteria Decision Analysis and Value Assessment Frameworks: Where Do We Stand? What Next? | Value in Health | Louis P Garrison | 2024/1/1 |
Estimating the Allocation of the Economic Value Generated by Utilization of All-Oral Direct-Acting Antivirals for Hepatitis C in the United States, 2015–2019 | Value in Health | Louis P Garrison Boshen Jiao Zizi Elsisi Alon Yehoshua Roy Koruth | 2024/4/23 |
The evolving value assessment of cancer therapies: Results from a modified Delphi study | Health Policy OPEN | Myrto Lee Hugo Larose Martin Gräbeldinger Jon Williams Anne-Marie Baird | 2024/3/1 |
The value of the accelerated approval pathway: real-world outcomes associated with reducing the time between innovations | Future Oncology | William Wong Stacey Kowal Tu My To Achal Patel David Veenstra | 2023/12 |
PCR33 An Updated Analysis of Hemophilia Patient Utility Study of Treatment Administration Impact: A Discrete Choice Experiment (DCE) Using Time Trade-Off (TTO) Methodology | Value in Health | M Benton D Hong M Skinner L Garrison M Karimi | 2023/6/1 |
1152. Quantifying the health equity related public health impact of national immunisation programmes | Open Forum Infectious Diseases | Eliana Biundo Mariia Dronova Annie Chicoye Richard Cookson Nancy Devlin | 2023/12 |
EE256 Comparative Cost-Utility Analysis of Galcanezumab and Fremanezumab for Migraine Prevention in Individuals with Chronic Migraine Who Have Tried 2 to 4 Prior Preventive … | Value in Health | S Bhardwaj M Zimmermann L Garrison | 2023/6/1 |
Estimating the lifetime medical cost burden of an allogeneic hematopoietic cell transplantation patient | Transplantation and Cellular Therapy | Richard T Maziarz Steven Devine Louis P Garrison Irene Agodoa Jack Badaracco | 2023/10/1 |
EE553 Estimating the Economic Burden of Progressive Multifocal Leukoencephalopathy in the United States: A Literature Review and Assessment | B Wang L Garrison | 2023/6/1 | |
Distributional Cost-Effectiveness Analysis of Treatments for Non-Small Cell Lung Cancer: An Illustration of an Aggregate Analysis and its Key Drivers | PharmacoEconomics | Aurelie Meunier Louise Longworth Manuel Gomes Sreeram Ramagopalan Louis P Garrison | 2023/8 |
Do future innovations in development influence oncologists’ treatment recommendations today? A survey of US oncologists. | Meng Li Zizi Elsisi William Bruce Wong Stacey Kowal David L Veenstra | 2023/6/1 | |
HSD65 From the Triple Aim to the Quintuple Aim to the ISPOR Value Flower: Are Health Systems Prepared for High-Value Cell and Gene Therapies? | Value in Health | L Garrison M Yen T Salimullah B Kazazoglu Taylor O Dabbous | 2023/6/1 |
HTA307 Evolving Principles for Defining and Assessing the Economic and Societal Value of Cancer Therapies | Value in Health | M Lee K Abrams AM Baird S Brown J Bruns | 2023/12/1 |
Assessing the potential cost-effectiveness of centralised versus point-of-care testing for hepatitis C virus in Pakistan: a model-based comparison | BMJ open | Joseph B Babigumira James K Karichu Samantha Clark Mindy M Cheng Louis P Garrison | 2023/5/1 |
HPR6 beyond conventional clinical value: estimating the impact of accelerated approvals on therapeutic bridging between innovative therapies | Value in Health | W Wong S Kowal TM To A Patel D Veenstra | 2023/6/1 |
Value Insider Season 1 Episode 5: What Other Aspects of Value May Be Relevant?(Societal Impact)[Podcast] | International Journal of General Medicine | Louis P Garrison Elisabeth Sophia Hartgers-Gubbels Michael Chambers | 2022 |
